Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prelude Therapeutics
Biotech
Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash
The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.
James Waldron
Nov 4, 2025 9:40am
Prelude calls it curtains on lead SMARCA2 cancer asset
Aug 14, 2025 10:44am
Pathos AI's $365M series D to fund trial of Novo tumor drug
May 15, 2025 10:20am
Prelude thinks SMARCA with AbCellera deal, culls 2 candidates
Nov 2, 2023 8:06am
3 more biotechs look to cull, partner assets
Nov 14, 2022 11:40am
Teon poaches Janssen US oncology head—Chutes & Ladders
Mar 11, 2022 9:30am
